Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects (ASCROD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01399749
Recruitment Status : Unknown
Verified July 2011 by Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz.
Recruitment status was:  Not yet recruiting
First Posted : July 22, 2011
Last Update Posted : July 22, 2011
Information provided by:
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

July 20, 2011
July 22, 2011
July 22, 2011
September 2011
June 2012   (Final data collection date for primary outcome measure)
Hyaline cartilage production for chondral knee lesions repair [ Time Frame: 18 months ]
Same as current
No Changes Posted
  • Efficacy: Clinical evolution [ Time Frame: 18 months ]
    Changes in Clinical tests and SF-12 Health Survey over 18 months
  • Efficacy: Functional evolution [ Time Frame: 18 months ]
    Changes in Western Ontario-McMaster Osteoarthritis Score(WOMAC) over 18 months
  • Efficacy: Functional evolution [ Time Frame: 18 months ]
    Changes in Knee Society Score(KSS) over 18 months
  • Efficacy: Histological evaluation [ Time Frame: 18 months ]
    Hyaline cartilage production by histological methods at 18 months
  • Efficacy: Radiological evaluation [ Time Frame: 18 months ]
    MRI at 18 months
  • Safety: Adverse events [ Time Frame: 18 months ]
    Sistemic and local AEs especially attributable to implanted cells
  • Safety: Acute inflammatory events [ Time Frame: 18 months ]
    Increase of pain of at least 30 mm on a 100 mm visual analog scale (VAS) along with self-reported swelling within 3 days post-cell application
Same as current
Not Provided
Not Provided
Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects
A Comparative Clinical Trial for the Repair of Chondral Knee Defects: Transplantation of Autologous Cultured Chondrocytes vs. Autologous Mesenchymal Stem Cells Derived From Adipose Tissue
The objective of our study is to compare the safety and effectiveness of the use of autologous cultured adipose tissue-derived stem cells versus cultured autologous chondrocytes for the treatment of chondral knee lesions.

Chondral knee lesions are frequent and produce important functional limitations and arthrosis development. Arthrosis is one of the most important causes of disability and its treatment with prosthetic surgery is associated with a high cost, and is not free of other complications. Several studies of cell therapy with autologous chondrocytes have shown efficacy in the treatment of this type of lesions, and currently is a common technique for the treatment of focal lesions of articular cartilage. Autologous chondrocyte transplant is associated with morbidity of the cartilage sample removal, which needs intra-articular surgery, and the limited tissue sample for culture. Adipose tissue-derived mesenchymal stem cells (ASC) have demonstrated chondrocytic differentiation and have been used in animal models for articular cartilage repair. Adipose tissue yields more ASC than chondrocytes are obtained from cartilage, and liposuction is simple and with less adverse events than arthroscopy. It is worth mentioned that culture conditions are less stringent for ASC than for chondrocytes, in terms of number of passages to obtain the amount of cells needed for implantation.

We propose a randomized clinical trial, in which we compare the surgical implantation of either autologous chondrocytes or autologous ASC to treat chondral knee lesions.

Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Articular Cartilage Lesion of the Femoral Condyle
Other: Implantation of autologous cells
Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
Other Name: ACI
  • Experimental: Autologous ASC implantation
    Treatment with autologous ASC
    Intervention: Other: Implantation of autologous cells
  • Active Comparator: Autologous Chondrocytes implantation
    Treatment with autologous chondrocytes
    Intervention: Other: Implantation of autologous cells

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
June 2012
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptomatic focal articular cartilage lesion on the medial femoral condyle
  • Lesion on femoral condyle between 1 and 5 cm²
  • ICRS Grade III/IV
  • Stable knee
  • Signed patient informed consent

Exclusion Criteria:

  • Clinically relevant member malalignment (> 5 degrees)
  • Non stable knee
  • Inflammatory joint disease
  • Knee surgery in the last year (transplant, suture or resection of the meniscus, mosaicplasty, microfracture)
  • Participation in concurrent trials or in the previous 3 months
  • Subjects with hepatitis, HIV or syphilis
  • Malignancy in the previous 5 years
  • Alcohol and/or drug abuse
  • Poor general health as judged by Investigator
  • Clinically relevant second cartilage lesion on the patella
  • Patellofemoral cartilage lesion
  • Known allergy to gentamicin or penicillins (or presence of multiple severe allergies)
  • Having received hyaluronic acid intra-articular injections in the affected knee within the last 6 months of baseline
  • Taking specific OA drugs such as chondroitin sulfate, diacerein, n-glucosamine, piascledine, capsaicin within 2 weeks of the baseline visit
  • Corticosteroid treatment by systemic or intra-articular route within the last month of baseline or intramuscular or oral corticosteroids within the last 2 weeks of baseline
  • Chronic use of anticoagulants
  • Uncontrolled diabetes
  • Any concomitant painful or disabling disease of the spine,hips or lower limbs that would interfere with evaluation of the afflicted knee
  • Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities
  • Liver enzymes (SGOT, SGPT, Alkaline Phosphatase) of more then two times the upper limit of normal or any other result that is clinically important according to the Investigator
  • CRP > 10 mg/l
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
2009-016628-29 ( EudraCT Number )
Not Provided
Not Provided
Alonso C. Moreno Garcia, La Paz University Hospital. Orthopedic Surgery and Traumatology Department
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
Not Provided
Principal Investigator: Alonso C. Moreno Garcia, MD Orthopedic Surgery and Traumatology Department. Knee Unit
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP